BFS Molecular is a global molecular diagnostics company intent on transforming and improving the way post-transplantation patient care is practised.
Early detection of transplant rejection or disease relapse is critical for the adjustment of a transplant recipient’s treatment regime, survival of the graft and for higher quality of life for patients.
Although there are some post transplant-monitoring products already on the market, the current Gold Standard approaches lack sensitivity and also in some cases specificity, potentially causing delays to treatment or even misdiagnosis.
BFS Molecular was founded in 2017. The CEO and co-founder is Tim Hague, who was previously the CEO of Omixon, a pre-transplant focused, global molecular diagnostics company.